Shots: Celgene has added four more immunotherapies (making it eight, to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product, using Dragonfly’s TriNKET technology Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene) TriNKET technology (Tri-specific, NK cell […]Read More
Tags : Solid and Hematological Cancers
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US